196 related articles for article (PubMed ID: 25572816)
1. Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X
Med Oncol; 2015 Feb; 32(2):464. PubMed ID: 25572816
[TBL] [Abstract][Full Text] [Related]
2. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Wei Z; Yang X; Ye X; Feng Q; Xu Y; Zhang L; Sun W; Dong Y; Meng Q; Li T; Wang C; Li G; Zhang K; Li P; Bi J; Xue G; Sun Y; Sheng L; Liu B; Yu G; Ren H; Wang J; Sun L; Chen S; Geng D; Zhang B; Xu X; Zhang L; Sun D; Xu X; Diao C; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zheng A; Fan W; Li Y; Li F; Fan H; Zou Z; Li Q; Tian H
Eur Radiol; 2020 May; 30(5):2692-2702. PubMed ID: 32020400
[TBL] [Abstract][Full Text] [Related]
3. Advanced non small cell lung cancer: response to microwave ablation and EGFR Status.
Wei Z; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
Eur Radiol; 2017 Apr; 27(4):1685-1694. PubMed ID: 27436020
[TBL] [Abstract][Full Text] [Related]
4. Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone.
Li C; Wang J; Shao JB; Zhu LM; Sun ZG; Zhang N
Thorac Cancer; 2019 Jul; 10(7):1628-1635. PubMed ID: 31243894
[TBL] [Abstract][Full Text] [Related]
5. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
6. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ
Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938
[TBL] [Abstract][Full Text] [Related]
7. Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer.
Wei Z; Ye X; Yang X; Zheng A; Huang G; Li W; Ni X; Wang J; Han X
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):135-42. PubMed ID: 24809754
[TBL] [Abstract][Full Text] [Related]
8. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
Ni Y; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
J Cancer Res Clin Oncol; 2020 Jan; 146(1):197-203. PubMed ID: 31599340
[TBL] [Abstract][Full Text] [Related]
9. Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.
Wei Z; Yang X; Ye X; Huang G; Li W; Han X; Wang J; Meng M; Ni Y; Zou Z; Wen Q
J Cancer Res Ther; 2019; 15(7):1629-1634. PubMed ID: 31939448
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
[TBL] [Abstract][Full Text] [Related]
11. Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.
Yan P; Tong AN; Nie XL; Ma MG
BMC Med Imaging; 2021 Jun; 21(1):96. PubMed ID: 34098894
[TBL] [Abstract][Full Text] [Related]
12. Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations.
Wei Z; Ye X; Yang X; Zheng A; Huang G; Li W; Wang J; Han X; Meng M; Ni Y
Oncotarget; 2017 Aug; 8(34):56714-56725. PubMed ID: 28915624
[TBL] [Abstract][Full Text] [Related]
13. Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Zhou F; Yu X; Liang P; Cheng Z; Han Z; Yu J; Liu F; Tan S; Dai G; Bai L
Int J Hyperthermia; 2016 Aug; 32(5):524-30. PubMed ID: 27055684
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography-guided microwave ablation for the treatment of non-small cell lung cancer patients with and without adjacent lobe invasion: A comparative study.
Xu S; Bie ZX; Li YM; Li B; Guo RQ; Li XG
Thorac Cancer; 2021 Oct; 12(20):2780-2788. PubMed ID: 34427998
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
16. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation.
Vogl TJ; Eckert R; Naguib NN; Beeres M; Gruber-Rouh T; Nour-Eldin NA
AJR Am J Roentgenol; 2016 Dec; 207(6):1340-1349. PubMed ID: 27680945
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study.
Cheng M; Fay M; Steinke K
Int J Hyperthermia; 2016 May; 32(3):316-23. PubMed ID: 26892261
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
19. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
